Table 2.
Trials investigating novel therapies in relapsed/refractory PMBCL
| Study | Study type | Treatment | Patient cohort | n | Outcome |
|---|---|---|---|---|---|
| Studies with a distinct PMBCL analysis | |||||
| Jacobsen et al (2015) | Single‐arm multicentre phase 2 trial; subset analysis | Brentuximab | ECOG PS 0‐2 | 6 | ORR 17% (1 CR) |
| Zinzani et al (2017c) | Single‐arm multicentre phase 2 trial | Brentuximab | ECOG PS 0‐1 | 15 | ORR 13·3% (2 PR) |
| Zinzani et al (2017a); Armand et al (2018) | Single‐arm multicentre phase 1b trial; subset analysis | Pembrolizumab | ECOG PS 0‐1 | 21 | ORR 48% (7 CR, 3 PR) |
| Studies with PMBCL included in cohort analysis | |||||
| Neelapu et al (2017) | Single‐arm multicentre phase 1–2 trial; subset analysis | CD19 targeted CAR‐T cells: KTE‐C19 (axicabtagene ciloleucel) |
RR PMBCL and transformed FL ECOG PS 0‐1 |
24 (8 PMBCL) | ORR 85% (CR 70%) |
| Armand et al (2013) | Single‐arm multicentre phase 2 trial | Pidilizumab |
RR PMBCL, DLBCL and transformed indolent lymphoma ECOG PS 0‐1 |
66 (4 PMBCL) | ORR 51% (CR 34%) |
CAR, chimeric antigen receptor; CR, complete response; DLBCL, diffuse large B‐cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; ORR, overall response rate; PMBCL, primary mediastinal B‐cell lymphoma; PR, partial response; RR, relapsed/refractory.